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Abstract
Background: Congenital dyserythropoietic anemia type II (CDAII), the most common form of CDA, is an autosomal
recessive condition. CDAII diagnosis is based on invasive, expensive, and time consuming tests that are available
only in specialized laboratories. The recent identification of SEC23B mutations as the cause of CDAII opens new
possibilities for the molecular diagnosis of the disease. The aim of this study was to characterize molecular
genomic SEC23B defects in 16 unrelated patients affected by CDAII and correlate the identified genetic alterations
with SEC23B transcript and protein levels in erythroid precursors.
Methods: SEC23B was sequenced in 16 patients, their relatives and 100 control participants. SEC23B transcript level
were studied by quantitative PCR (qPCR) in peripheral erythroid precursors and lymphocytes from the patients and
healthy control participants. Sec23B protein content was analyzed by immunoblotting in samples of erythroblast
cells from CDAII patients and healthy controls.
Results: All of the investigated cases carried SEC23B mutations on both alleles, with the exception of two patients
in which a single heterozygous mutation was found. We identified 15 different SEC23B mutations, of which four
represent novel mutations: p.Gln214Stop, p.Thr485Ala, p.Val637Gly, and p.Ser727Phe. The CDAII patients exhibited a
40-60% decrease of SEC23B mRNA levels in erythroid precursors when compared with the corresponding cell type
from healthy participants. The largest decrease was observed in compound heterozygote patients with missense/
nonsense mutations. In three patients, Sec23B protein levels were evaluated in erythroid precursors and found to
be strictly correlated with the reduction observed at the transcript level. We also demonstrate that Sec23B mRNA
expression levels in lymphocytes and erythroblasts are similar.
Conclusions: In this study, we identified four novel SEC23B mutations associated with CDAII disease. We also
demonstrate that the genetic alteration results in a significant decrease of SEC23B transcript in erythroid precursors.
Similar down-regulation was observed in peripheral lymphocytes, suggesting that the use of these cells might be
sufficient in the identification of Sec23B gene alterations. Finally, we demonstrate that decreased Sec23B protein
levels in erythroid precursors correlate with down-regulation of the SEC23B mRNA transcript.
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Background
Congenital dyserythropoietic anemias (CDAs) are a
group of rare hereditary disorders characterized by inef-
fective erythropoiesis and distinct morphological
abnormalities of the erythroblasts in the bone marrow
[1]. CDA type II (CDAII, OMIM 224100), which is
transmitted as an autosomal recessive condition, is the
most frequent; the main European Registries (German,
Italian and French) have counted 367 patients [2]. The
clinical picture is characterized by mild to moderate
anemia associated with jaundice, splenomegaly, and iron
overload [3,4]. In clinical practice, evidence of CDAII is
primarily based on bone marrow examination [5,6].
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any medium, provided the original work is properly cited.Confirmation of diagnosis is based on at least one of the
following biochemical tests, including: a positive acid
serum lysis test with ABO-compatible sera; band 3 pro-
tein glycosylation defects evidenced by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE); a discontinuous double membrane in mature
erythroblasts (visible by electron microscopy), and the
presence of endoplasmic reticulum (ER)-specific pro-
teins [5,7-9]. However, these tests are expensive, time
consuming, and often available in only a few specialized
laboratories. For these reasons, the correct diagnosis of
CDAII is often delayed or erroneously suspected.
A major breakthrough in CDAII research was
achieved in 2009, when Schwarz et al. and Bianchi et al.
found mutations of the SEC23B gene in patients with
CDAII [10,11]. Sec23B protein is an essential compo-
nent of coat protein complex II (COPII), coated vesicles
that transport secretory proteins from the ER to the
Golgi complex [12]. So far, SEC23B changes have been
identified mainly by direct genomic sequencing of the
coding region of the gene [10,11,13-15]; however, the
precise effects of the described mutations on the RNA
expression level in erythroid cells has not been studied.
Moreover, a reduction of Sec23B protein in CDAII ery-
throid precursors has not been reported.
In this study, we investigated SEC23B gene mutations,
by both genomic and cDNA direct sequencing, in 16
unrelated Italian CDAII patients from 16 families. In all
cases, we identified SEC23B mutations, and four of
these were novel. We also evaluated the effects of differ-
ent SEC23B mutations on mRNA and protein expres-
sion levels.
Methods
Patients
We collected blood samples from 16 unrelated Italian
CDAII patients belonging to 16 families and 100 unre-
lated Italian controls (included in the DNA sequence
analyses). The diagnosis of CDAII was made on the
basis of clinical features, bone marrow examination,
and/or SDS-PAGE. All patients provided their written
informed consent for the study, which was approved by
the research ethics committee of the Second University
of Naples, Italy. The study was conducted in accordance
with the Declaration of Helsinki.
Erythroid precursor cultures
After informed consent had been obtained, peripheral
blood from CDA II patients and from 5 healthy control
relatives was collected into sterile heparinised tubes.
Light-density mononuclear cells obtained by centrifuga-
tion on Lymphoprep (Nycomed Pharma) density gradi-
ent were enriched for CD34
+ cells by positive selection
using CD34 microbeads (Miltenyi Biotech) according to
the manufacturers’ instructions. CD34
+ cells were cul-
t u r e da tad e n s i t yo f1 0
5 cells/mL in alpha-minimal
essential medium (a-MEM; GIBCO) supplemented with
30% fetal bovine serum (FBS; GIBCO), as previously
described [16]. To induce cells proliferation and ery-
throid differentiation, cells were cultured with 20 ng/mL
rH stem cell factor (SCF, PeproTech), 10 ng/mL rH
interleukin-3 (IL-3, PeproTech) and 3 U/mL recombi-
nant human (rH) erythropoietin (rHuepo, Janssen-
Cilag). Cells were incubated at 37°C with an atmosphere
of 5% CO2 for 14 days; after 7 days of culture the med-
ium was changed to ensure good cells feeding. Cell sam-
ples were collected on days 14 of culture (mature
erythroblast stage) for further analysis.
Molecular analysis of the SEC23B gene
Genomic DNA was isolated using the Flexigene DNA
extraction kit (Qiagen). All SEC23B exons, their flanking
splice junctions, and their 5’-a n d3 ’-untranslated
regions were amplified with 21 polymerase chain reac-
tions (PCRs). cDNA was prepared, using the iScript
cDNA synthesis kit (Bio-Rad), from approximately 100
ng mRNA obtained from lymphocytes (Trizol Reagent
Kit - Invitrogen) from all 16 patients and 8 healthy con-
trol relatives. cDNA was obtained also from erythro-
blasts [16] from 8 patients (ID: F1, G2, B3, A4, C5,
B11P13, and M15) and 5 of the 8 healthy control rela-
tives mentioned above. The coding region of the
SEC23B cDNA was covered by six PCR fragments.
Sequences of all primers can be found in Table 1. The
PCR conditions were: 94°C for 5 min; 30 cycles of 94°C
for 30 sec, 58°C for 30 sec and 72°C for 30 sec; and 72°
C for 7 min. Amplified DNA and cDNA were purified
(Exo-Sap-IT) and sequenced using BDT v3.1 on an
ABIPrism 3130XL genetic analyzer. Sequences were ana-
lyzed using the SeqScape program, version 2.6 (Applied
Biosystems).
Table 1 Primer sequences for SEC23B cDNA amplification
Oligo Name Oligo Sequence
SEC23B cDNA 1F ACCTGTCTTGCCCTGTTCC
SEC23B cDNA 1R TACAGGCCCAAAGTTTTGCT
SEC23B cDNA 2F AGCAGGCCAACTTGTAAAGC
SEC23B cDNA 2R CTTGAAGCAAAAGGGTGCTC
SEC23B cDNA 3F ACAGGATATGTTGGGCCTGA
SEC23B cDNA 3R TTGCACAACACTTCATCTCCA
SEC23B cDNA 4F GAACAGCTGCAAATGGTCAC
SEC23B cDNA 4R CACAGTCGGATGAGTTGTCG
SEC23B cDNA 5F GACCGACAACTCATCCGACT
SEC23B cDNA 5R TTTCCTGTCCCCAAGCATAC
SEC23B cDNA 6F CAGTCAGGCTCGATTCCTTT
SEC23B cDNA 6R CACCTAAACAAGCTGCCAAA
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cDNA was prepared from patients’ mRNA from lym-
phocytes and erythroblasts. Real-time PCR was per-
formed in accordance with manufacturers’ instructions.
The reactions were run on an ABI 7300 real-time PCR
system (Applied Biosystems); the cycling conditions
were 10 min at 95°C (initial denaturation) followed by
40 cycles of 15 sec at 94°C (denaturation) and 1 min at
68°C (annealing/extension/data collection). In the first
step, we determined the stability of a control gene (b-
actin) for the normalization of the real-time PCR pro-
ducts. The linearity and efficiency of this assay were
tested over dilutions of input cDNA spanning five
orders of magnitude. Assays were performed in tripli-
cate. We used the 2
-ΔΔCt method to analyze the data
obtained.
Western blotting
Proteins were extracted from erythroid cultures of
patients A4, B3, and C5 using RIPA Lysis Buffer (Milli-
pore) and following the manufacturer’s instructions.
Sec23B was characterized in total lysates from erythroid
cultures by Western blotting. Membranes were incu-
bated overnight at 4°C with rabbit polyclonal anti-
Sec23B antibody (1:500 dilution; SAB2102104, Sigma-
Aldrich); reactive bands were detected by chemilumines-
cence (SuperSignal). An anti-b-actin antibody (1:500
dilution; Sigma) was used to check for comparable pro-
tein loading and as a housekeeping protein. Images were
captured, stored, and analyzed using Quantity One soft-
ware (BioRad).
Results
Molecular analysis of the SEC23B gene
We identified SEC23B mutations in all 16 patients
enrolled in the study. Among the 15 mutations charac-
terized, four are novel: c.640C > T, c.1453A > G,
c.1910T > G, and c.2180C > T (Table 2). In total, we
identified 10 missense, three nonsense, one in-frame
deletion of 3 nucleotides, and one splice-site mutation.
The splice-site alteration creates a new donor site after
e x o n2o ft h eSEC23B gene. Most of the investigated
patients were compound heterozygotes. Only four
patients had homozygous SEC23B mutations; three of
these were homozygotes for the c.325G > A variant that
leads to the amino acid change p.Glu109Lys (the most
frequent SEC23B mutation encountered, with a preva-
lence of 32% among CDAII patients). The fourth patient
was homozygous for the c.1254T > G mutation (p.
Ile418Met).
In two patients, we observed only a single heterozy-
gous mutation (Table 2). Because individuals with a
heterozygous SEC23B mutation are not affected by
CDAII, we investigated in detail the putative occur-
rence of heterozygous exon deletions/insertions in the
alternative allele in these patients. PCR of cDNA using
primers located in the 5’ and 3’ untranslated regions of
the gene revealed full-length transcript in both patients
and no aberrant products, excluding the presence of
heterozygous exon deletions/insertions. cDNA
sequence analysis confirmed the heterozygous missense
mutation and the presence of two alleles (i.e., wild-type
and mutant).
Table 2 SEC23B mutations in 16 Italian patients
Patient
ID
Allele
1
Allele
2
Protein
change 1
Protein
change 2
cDNA
%
F1 c.953 T > C c.1910 T > G p.Ile318Thr p.Val637Gly 55
G2 c.40 C > T c.1015 C > T p.Arg14Trp p.Arg339X 42
B3 c.325 G > A c.325 G > A p.Glu109Lys p.Glu109Lys 60
A4 IVS1 +31 A > G c.367 C > T Donor site ins p.Arg123X 36
C5 c.40 C > T c.1857-1859delCAT p.Arg14Trp p.I619del 54
C6 c.40 C > T c.2101 C > T p.Arg14Trp p.Arg701Cys 62
P7 c.40 C > T c.1015 C > T p.Arg14Trp p.Arg339X 42
C9 c.40 C > T - p.Arg14Trp - 58
D10 c.325 G > A c.325 G > A p.Glu109Lys p.Glu109Lys 60
B11 c.1453 A > G c.1589 G > A p.Thr485Ala p.Arg530Gln 55
P13 c.40 C > T c.640 C > T p.Arg14Trp p.Gln214X 50
G14 c.325 G > A c.325 G > A p.Glu109Lys p.Glu109Lys 61
M15 c.40 C > T c.2180 C > T p.Arg14Trp p.Ser727Phe 55
F16 c.325 G > A c716 A > G p.Glu109Lys p.Asp239Gly 61
P17 c.40 C > T - p.Arg14Trp - 64
E18 c.1254 T > G c.1254 T > G p.Ile418Met p.Ile418Met 53
Novel mutations are bold
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patients. In all cases, the mutations identified by geno-
mic analysis were confirmed by cDNA sequencing. Even
in the patients carrying nonsense mutations (which
most likely lead to RNA decay), it was possible to visua-
l i z et h eg e n e t i cc h a n g eb yc D N As e q u e n c i n g( F i g u r e
1A). None of the novel mutations described in this
study was found in 100 unrelated Italian controls. All
mutations were absent from the 1094 individuals from
the 1000Genomes project.
Real-time PCR
To directly evaluate the consequences of the genomic
SEC23B mutations, we investigated SEC23B mRNA
levels in patients and healthy individuals using quanti-
tative PCR (qPCR). Patients that were compound het-
erozygotes for a missense and a nonsense mutation
exhibited a drastic decrease in mRNA expression levels
of approximately 50-60% when normalized to the
endogenous control gene b-actin (Table 2 and Figure
1B). Patients with two missense mutations showed a
milder reduction in SEC23B mRNA levels (approxi-
mately 40-45%) (Table 2). The results were similar
when using RNA from lymphocytes or mature erythro-
blasts (Figure 1B and data not shown). The two
patients with a single heterozygous mutation on
SEC23B (C9 and P17) also exhibited a reduction of
SEC23B transcript (Table 2).
Figure 1 A) Electropherogram depicting the nonsense mutation (c.367C > T) observed after DNA and cDNA sequencing; B) Relative
SEC23B mRNA expression levels in lymphocytes and erythroblasts from patients with nonsense/missense mutations compared with
healthy controls.
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mutation (c.221+31A > G) and a nonsense change
(c.367C > T). In this individual, we suspected very low
or no wild-type (WT) transcript. Therefore, we investi-
gated A4 SEC23B mRNA more in detail. First, the pre-
sence of the +31A > G allele was confirmed on agarose
gel by the presence of an additional 31-bp band. In the
other allele, the nonsense mutation creates a restriction
site for the enzyme HpyCH4III. After enzymatic diges-
tion of the PCR product with HpyCH4III restriction
enzyme, we observed four fragments: an upper band for
the + 31A < G allele, two lower bands representing the
cut allele carrying the nonsense mutation, and a nor-
mal-sized band (Figure 2). The occurrence of a normal
transcript indicates that at least a small amount of WT
SEC23B RNA is present. This finding corresponds to
the observed 35-40% SEC23B mRNA expression level
measured by qPCR.
Western blotting
Finally, we investigated the amount of Sec23B protein in
the erythroblasts of 3 CDAII patients (C5, B3 and A4)
by immunoblotting. The Sec23B content was normalized
to b-actin. As depicted in Figure 3A, the Sec23B content
of patients C5 and B3 was clearly reduced compared to
two different controls. Similar results were obtained in
two independent experiments. Moreover, the estimated
Sec23B protein level in erythroblasts from patient A4
suggested that it corresponded to approximately 30-35%
of that of a healthy individual (Figure 3B). Therefore,
our data suggest good correspondence between the tran-
script amount and protein content, underscoring the
usefulness of mRNA evaluation.
Discussion
In this study, we identified four novel SEC23B gene
mutations by analyzing 16 Italian patients with CDAII
(Table 2). We also identified two CDAII patients with
only one heterozygous mutation each.
Since the initial identification of SEC23B mutations in
CDAII patients, 59 mutations have been identified,
including the current work (Table 3) [10,11,13-15,17,18].
Two missense mutations have been repeatedly identified
in a large proportion of patients: p.Glu109Lys and p.
Figure 2 Characterization of SEC23B mutations in patient A4. Lymphocytic cDNA was amplified using primers localized in exons 1 and 4 (A4-
SEC23B-1F: TTGTACCCCTGGCTTGTCTC and A4-SEC23B-4R: ATGAACCTGCACCATCCTTC). The control shows the 425-bp product (wild-type, W.T.); (1)
Patient A4: Two bands (456-bp and 425-bp) were present. The additional 456-bp band is due to the splicing mutation: c.221+31 A > G; (2) The
nonsense mutation (c.367 C > T) creates a restriction site for the enzyme HpyCH4III. SEC23B PCR product from patient A4 was enzymatically digested.
The two resulting bands (262-bp and 163-bp) represent the cut allele carrying the nonsense mutation. M.W. = Molecular Weight.
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missense mutations account for approximately 50% of
the mutant alleles in CDAII patients (Table 3). Notably,
evidence of a founder effect has been described for p.
Glu109Lys among Israeli Moroccan Jewish patients [13].
Concerning mutation type, missense (52%) and non-
sense (21%) mutations are the most commonly observed
followed by deletions or insertions that lead to frame-
shifts in the nucleotide sequence. Splicing mutations are
rare, with only six mutations reported (Table 3).
The SEC23B gene appears to play a pivotal and prob-
ably unique function in erythroid precursors [19,20].
Although detailed genetic analyses have been conducted,
the effects of the mutations on mRNA content in ery-
throblast cells have not been documented. Moreover, no
data are available about the effects of mutations on
Sec23B protein content in red cell precursors.
To evaluate the effect of missense and nonsense muta-
tions on SEC23B mRNA expression levels, we per-
formed quantitative (qPCR) analysis of SEC23B
transcripts on all of our patients. In this study, we used
both cDNAs prepared from erythroid precursor cultures
and peripheral lymphocytes. Although we demonstrate
that all patients have a significant reduction of SEC23B
mRNA, this reduction was more pronounced in patients
with missense/nonsense mutations (Table 2). From a
diagnostic point of view, it is interesting to note that the
results obtained in erythroid precursors and lympho-
cytes were comparable, suggesting that peripheral lym-
phocytes not only represent a good source of SEC23B
transcript, but also replicate the effect of the genetic
change observable in the erythroid population.
In addition, to search for genotype-phenotype correla-
tion, we grouped patients according to their degree of
anemia. We did not observe any correlation between
degree of anemia, type of mutation, and relative SEC23B
mRNA reduction (data not shown).
Almost all CDAII patients harbor mutations in both
SEC23B alleles. In a few cases (10 out of 111 described
in the literature, or 9%), only a single heterozygous
SEC23B mutation has been found. This finding raises
the possibility of the occurrence of mutations that have
thus far escaped the exon screening technology. In our
study, two CDAII patients were identified in whom a
mutation was observed in only one allele. In these parti-
cipants, mRNA analysis (cDNA sequencing and long-
range PCR on cDNA) confirmed the presence of both
wild-type and mutated alleles. However, qPCR analysis
revealed a reduction in SEC23B mRNA expression of
approximately 40% in these patients compared with con-
trol participants, similar to the reduction observed in
patients with two missense mutations. This finding sug-
gests the possible occurrence of mutations that affect
t h er e g u l a t o r yr e g i o n so ft h eSEC23B gene. Alternate
Figure 3 Sec23B protein analysis in erythroid precursors. Western blots from patients C5 and B3 (panel A), and A4 (panel B) demonstrate
reduced Sec23B expression compared with control participants (Con). Approximately 40 μg of protein were loaded. b-actin was used as a
loading control. The experiment was representative of two different experiments.
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Exon/Intron Nucleotide change Protein change Type of mutation Allelic frequency, n (%) References
2 c.40 C > T p.Arg14Trp Missense 48 (19) [11]
2-3 c.221+31 A > G - Splice-site change* 2 (0.8) [14]
2 c.53 G > A p.Arg18His Missense 3 (1.2) [11]
2 c.197 G > A p.Cys66Tyr Missense 1 (0.4) [17]
3 c.235 C > T p.Arg79X Non-sense 3 (1.2) [11]
3-4 c.279 +3 A > G - Splice-site change 1 (0.4) [14]
3-4 c.222-817_366+4242del - Frame-shift 1 (0.4) [11]
4 c.325 G > A p.Glu109Lys Missense 81 (32) [11]
5 c.367 C > T p.Arg123X Non-sense 2 (0.8) [14]
5 c.387(delG) p.Leu129LeufsX26 Frame-shift 1 (0.4) [14]
5 c.428delAinsCG - Frame-shift 1 (0.4) [10]
5 c.568 C > T p.Arg190X Non-sense 1 (0.4) [10]
6 c.640 C > T p.Gln214X Non-sense 1 (0.4) Present study
6 c.649 C > T p.Arg217X Non-sense 4 (1.6) [10]
6-7 c.689+1G > A - Splice-site change 4 (1.6) [10]
7 c.716 A > G p.Asp239Gly Missense 3 (1.2) [11]
7 c.790 C > T p.Arg264X Non-sense 3 (1.2) [11]
8 c.938 G > A p.Arg313His Missense 4 (1.6) [11]
8 c.953 T > C p.Ile318Thr Missense 6 (2.4) [11]
8 c.970 C > T p.Arg324X Non-sense 2 (0.8) [11]
9 c.1015 C > T p.Arg339X Non-sense 3 (1.2) [14]
9 c.1043 A > C p.Asp348Ala Missense 1 (0.4) [10]
9 c.1063delG - Frame-shift 1 (0.4) [11]
9-10 c.1109 +5 G > A - Splice-site change 1 (0.4) [14]
9-10 c.1190 +1 G > A - Splice-site change 1 (0.4) [14]
10 c.1157 A > T p.Gln353Leu Missense 1 (0.4) [11]
10 c.1201 C > T p.Arg401X Non-sense 1 (0.4) [11]
11 c.1254 T > G p.Ile418Met Missense 3 (1.2) [14]
11 c.1276 G > A p.V426I Poly Missense 2 (0.8) [11]
11 c.1307 C > T p.Ser436Leu Missense 1 (0.4) [14]
12 c.1385 A > G p.Tyr462Cys Missense 6 (2.4) [11]
13 c.1453 A > G p.Thr485Ala Missense 1 (0.4) Present study
13 c.1489 C > T p.Arg497Cys Missense 9 (3.6) [10]
13 c.1508 G > A p.Arg503Gln Missense 1 (0.4) [18]
14 c.1571 C > T p.Ala524Val Missense 5 (2) [11]
14 c.1588 C > T p.Arg530Trp Missense 1 (0.4) [11]
14 c.1589 G > A p.Arg530Gln Missense 2 (0.8) [18]
14 c.1603 C > T p.Arg535X Non-sense 2 (0.8) [14]
14 c.1648 C > T p.Arg550X Non-sense 4 (1.6) [18]
14 c.1654 C > T p.Leu552Phe Missense 1 (0.4) [14]
14 c.1660 C > T p.Arg554X Non-sense 2 (0.8) [10]
15 c.1685 A > G p.Tyr562Cys Missense 1 (0.4) [18]
15 c.1733 T > C p.Leu578Pro Missense 2 (0.8) [14]
15 c.1735 T > A p.Tyr579Asn Missense 1 (0.4) [14]
16 c.1808 C > T p.Ser603Leu Missense 1 (0.4) [10]
16 c.1821delT - Frame-shift 3 (1.2) [10]
16 c.1832 G > C p.Arg611Pro Missense 1 (0.4) [14]
16 c.1858 A > G p.Met620Val Missense 2 (0.8) [14]
16 c.1857_1859delCAT p.Ile619del In frame deletion** 2 (0.8) [14]
17 c.1910 T > G p.Val637Gly Missense 1 (0.4) Present study
17 c.1962-64delT p.Thr654ThrfsX13 Frame-shift 1 (0.4) [18]
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responsible for CDAII in these cases where the second
heterozygote mutation has not been found.
Here we demonstrate that SEC23B mutations result in
reductions of both the relative transcript and protein
content in erythoid precursors. So far, only one study
has investigated protein levels of Sec23B in CDAII
patients [11]. No reduction of Sec23B protein levels was
observed, most likely due to the type of cell used in the
study (fibroblasts). Our data, although comprising a
small number of cases, clearly demonstrate that CDAII
erythroblastoid cells show a strong reduction of the pro-
tein that parallels the data regarding mRNA levels.
Future investigations are necessary to clarify the effect
of protein reduction on the patients’ phenotype.
Patients lacking Sec23B expression have never been
described. We identified a single patient (A4) with a
nonsense mutation and a splice site mutation (c.221+31
A > G) that causes a stop codon after exon 1. In our
view, this patient could have had a very strong reduction
of Sec23B expression. On the basis of this hypothesis,
we analyzed the amount of SEC23B mRNA and protein
in this patient in detail. The results demonstrate that
there is still a small amount of WT SEC23B mRNA and
that the Sec23B protein level in this patient corresponds
to 30% of the level observed in healthy participants, sug-
gesting that the absence of SEC23B expression may be
lethal.
Conclusions
This study reports SEC23B gene mutations in all 16
CDAII patients studied, confirming the causative rele-
vance of the gene to the condition. We also demon-
s t r a t e dt h a tt h eSEC23B gene mutations lead to a
remarkable reduction of SEC23B transcript in erythroid
precursors, the cell type altered in the disease. We also
demonstrated that quantifying and sequencing SEC23B
mRNA from peripheral lymphocytes (and not only from
erythroid cultures) might facilitate the genetic diagnosis
of CDAII. Our data on heterozygote patients suggest
(although indirectly) the occurrence of rare mutations is
not restricted to its coding regions. Finally, we demon-
strate that the relative mRNA reduction directly corre-
sponds to a protein decrease in erythroblastoid cells.
Future studies will be devoted to characterizing the
effect of SEC23B protein down-regulation on erythro-
poiesis and clarifying SEC23B gene regulation.
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Table 3 Summary of all SEC23B mutations in CDAII patients, predicted effect on protein and allelic frequencies
(Continued)
17 c.1968 T > G p.Phe656Leu Missense 1 (0.4) [18]
18 c.2101 C > T p.Arg701Cys Missense 9 (3.6) [10]
18 c.2129 C > T p.Thr710Met Missense 1 (0.4) [13]
18-19 c.2149 -2 A > G - Splice-site change 2 (0.8) [14]
19 c.2150(delC) p.Ala717ValfsX7 Frame-shift 1 (0.4) [14]
19 c.2166 A > C p.Lys723Gln Missense 1 (0.4) [18]
19 c.2180 C > T p.Ser727Phe Missense 1 (0.4) Present study
20 c.2270 A > C p.His757Pro Missense 1 (0.4) [14]
*creation of a new donor site
**1 aminoacid deletion
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